Daiichi Sankyo Company, Limited and Eli Lilly and Company have announced data from the TRILOGY ACS study, a phase III...
A study shows that pre-treatment with Efient/Effient (prasugrel hydrochloride), from Daiichi Sankyo and Eli Lilly, prior to catheterization, significantly increases...
Merck Inc.,has announced that it will cease marketing Zontivity (vorapaxar) ,a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of...
The FDA has accepted a supplemental new drug application (sNDA) and granted Priority Review for Brilinta (ticagrelor) tablets, from AstraZeneca,...
Brilinta (ticagrelor), from AstraZeneca, works faster and is more effective in blocking platelet activity in low-risk patients with acute coronary...